ClinicalTrials.gg
CompletedNCT00765674Updated May 9, 2011Results posted

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

A Phase 3 interventional study of Aliskiren and Amlodipine in Hypertension, sponsored by Novartis. Completed at 12 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-09.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,191
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
7th of 89
1,191 · median 253
Started
2008
with 11 others
Phase 3
38 of 89
none open now
Registered
49th of 89
by date
Lead sponsor
52 of 89
Novartis

Among the 89 studies testing aliskiren in Hypertension, this one is the 7th largest by enrollment, is one of 12 that started in 2008, is one of 38 in phase 3, and was the 49th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • aliskiren
  • antihypertensive
  • hypertension
  • renin inhibitor
  • moderate-severe hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • 18 years of age or older
  • msDBP and msSBP requirements:

    • 3A:

      • Diagnosis of moderate to severe hypertension (msSBP ≥ 160 mmHg and \< 200 mmHg, and/or msDBP ≥ 100 mmHg and \< 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)
      • In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP ≥ 145 mmHg and \< 200 mmHg and msDBP ≥ 95 mmHg and \< 120 mmHg) at Visits 3, 5 or 5.
      • Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.
    • OR
    • 3B:

      • msSBP ≥ 180 mmHg and \< 200 mmHg with msDBP ≥ 95 mmHg and \< 120 mmHg, or msDBP ≥ 110 mmHg and \< 120 mmHg with msSBP ≥ 150 mmHg and \< 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).

Exclusion criteria

Exclusion Criteria:

  • Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start
  • Patients with an msSBP ≥ 200 mmHg or msDBP ≥ 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.
  • Extremely elevated (defined) blood pressure at any point during the study
  • Pregnant or lactating women
  • Pre-menopausal women not taking accepted form of
  • History or evidence of secondary form of hypertension
  • History of cardiovascular conditions

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,191 participants (actual)

Study arms

  • Experimental
    Aliskiren / amlodipine

    Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

    Drug: Aliskiren · Drug: Amlodipine · Drug: Placebo

  • Experimental
    Aliskiren / hydrochlorothiazide

    Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

    Drug: Aliskiren · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo

  • Experimental
    Amlodipine / hydrochlorothiazide

    Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

    Drug: Amlodipine · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo

  • Experimental
    Aliskiren / amlodipine / hydrochlorothiazide

    Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

    Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide (HCTZ) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

  2. Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)

    Blood pressure control was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.

    Time frame: End of study (Week 8)

  3. Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)

    Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.

    Time frame: Baseline to end of study (Week 8)

07

Results

Posted May 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Started287298296310
Completed266276279285
Not completed21221725
Withdrew: Adverse event72811
Withdrew: Abnormal laboratory value(s)0010
Withdrew: Abnormal test procedure result(s)1312
Withdrew: Lack of efficacy2312
Withdrew: Protocol violation2010
Withdrew: Withdrawal by subject5738
Withdrew: Lost to follow-up4621
Withdrew: Randomized in error - no study drug0101

Outcome measures

PrimaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
mmHgAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)-31.37 ± 0.90-27.99 ± 0.88-30.77 ± 0.88-37.92 ± 0.86
SecondaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was \< 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
mmHgAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)-18.03 ± 0.57-14.32 ± 0.55-17.03 ± 0.55-20.63 ± 0.54
SecondaryPercentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)

Blood pressure control was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)
Percentage of patientsAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)41.333.139.062.3
SecondaryChange in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)

Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8. The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained. If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures. On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours. The ABPM data were downloaded and evaluated on site.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)
mmHgAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Systolic BP-20.30 ± 0.52-16.27 ± 0.51-18.67 ± 0.53-25.29 ± 0.51
Diastolic BP-13.29 ± 0.36-9.57 ± 0.35-11.20 ± 0.37-15.90 ± 0.35

Adverse events

Collected over During the 8 week double blind treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren / Amlodipine—3/287 (1%)32/287 (11.1%)
Aliskiren / Hydrochlorothiazide—2/297 (0.7%)17/297 (5.7%)
Amlodipine / Hydrochlorothiazide—2/295 (0.7%)26/295 (8.8%)
Aliskiren / Amlodipine / Hydrochlorothiazide—6/309 (1.9%)29/309 (9.4%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Hepatitis AInfections and infestations1/2870/2970/2950/309
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/2870/2970/2950/309
Nasal septum deviationRespiratory, thoracic and mediastinal disorders1/2870/2970/2950/309
Cerebrovascular accidentNervous system disorders0/2870/2971/2950/309
EpistaxisRespiratory, thoracic and mediastinal disorders0/2870/2971/2950/309
Tubo-ovarian abscessInfections and infestations0/2871/2970/2950/309
Stress urinary incontinenceRenal and urinary disorders0/2871/2970/2950/309
Acute coronary syndromeCardiac disorders0/2870/2970/2951/309
Arrhythmia supraventricularCardiac disorders0/2870/2970/2951/309
GoitreEndocrine disorders0/2870/2970/2951/309
Most frequent other events
Most frequent other events
EventAliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / Hydrochlorothiazide
Oedema peripheralGeneral disorders23/2876/29712/29522/309
HeadacheNervous system disorders9/28712/29715/29511/309

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / HydrochlorothiazideTotal
Mean54.4 ± 11.3355.5 ± 10.7555.1 ± 10.8655.4 ± 10.5455.1 ± 10.86
Age, Customized
Age, Customized(participants)Aliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / HydrochlorothiazideTotal
< 65 years237242233251963
>=65 years50566359228
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren / AmlodipineAliskiren / HydrochlorothiazideAmlodipine / HydrochlorothiazideAliskiren / Amlodipine / HydrochlorothiazideTotal
Female115123110123471
Male172175186187720
08

Study locations

12 sites
  • Investigative Site
    Denver, Colorado, United States
  • Investigative Site
    Sydney, Australia
  • Investigative Site
    Ottawa, Canada
  • Investigative Site
    Copenhagen, Denmark
  • Investigative Site
    Berlin, Germany
  • Investigative Site
    Jerusalem, Israel
  • Investigative Site
    Rome, Italy
  • Investigative Site
    Riga, Latvia
  • Investigative Site
    Vilnius, Lithuania
  • Investigative Site
    Bucharest, Romania
  • Investigative Site
    Stockholm, Sweden
  • Investigative Site
    Ankara, Turkey
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2008
First posted
Oct 3, 2008
Start
Sep 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
May 9, 2011
Last update
May 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00765674
Lead sponsor
Novartis
First posted
Oct 3, 2008
Start date
Sep 2008
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
May 9, 2011
Last update
May 9, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine · Hydrochlorothiazide

Start the discussion